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Abstract: A reliable and sensitive high performance liquid chromatographic method for the determination of widely 
prescribed antidepressant has been developed. Paroxetine is a potent selective serotonin reuptake inhibitor used for the 
treatment of depression and various mood disorders. The optimum mobile phase was prepared using a combination of 
40% acetonitrile and phosphate buffer 0.01 M to pH 3 and running under isocratic mode at a flow rate of 1.0 ml/min. with 
electrochemical detection at 0.9V. The applicability of the developed method is in the field of quality control as well as 
for monitoring the level of drug at various concentrations during synthesis of the parent drug. The suggested methodology 
was validated following the guidelines of the FDA in terms of: sensitivity (LOD and LOQ, 0.005 and 0.01 ng/mL, 
respectively), linearity between 0.5 - 50 ng/mL (r2 > 0.9999), inter- and intraday precision (< 0.259% and < 0.538%), 
robustness (less than 5.0%) and recovery (99.7 - 100.7%). The developed method is specific, rapid (less than 10 min), 
precise, reliable, accurate, cheap and suitable for routine analysis for the determination of paroxetine in pharmaceutical 
preparations. 
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1. INTRODUCTION 
 In the last few years prescription of antidepressants has 
increased many folds. The increase in the number of patients 
suffering with depression has indeed elevated the sale of 
antidepressants. The new drugs that enhance serotoninergic 
neurotransmission by potent and selective inhibition of 
serotonin are highest amongst the prescribed antidepressants, 
they are known as selective serotonin re-uptake inhibitors 
(SSRIs) [1]. Paroxetine, (-)-trans-4-(4-fluorophenyl)-3-(3, 4-
methylenedioxy-phenoxymethyl) piperidine, is one of the 
SSRIs used widely as an antidepressant drug alone, or in 
combination, with other drugs [2]. Paroxetine is comparable 
to the tricyclic antidepressants in their clinical efficacy, 
however, it is safer and has greater acceptance by the 
patients. Paroxetine is devoid of sedative effect and 
remarkably safe in overdose also. It takes 5.2 hours to reach 
the peak plasma level, with extended half life (21 hours) that 
allowed the introduction of formulations for once daily 
dosing. These combined qualities made paroxetine the most 
widely prescribed antidepressants [3]. It is normally used in 
the treatment of clinical depression, obsessive-compulsive 
disorder, and panic disorder [4]. In a survey performed by 
National Drug Code Health (Atlanta, GA, USA) in 2002,  
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paroxetine was one of the top 200 prescriptions for 2002 by 
number of U.S. prescriptions dispensed 
 The increase in the demand of the antidepressant drug 
has unfortunately invited supply of fake or counterfeit drugs 
in the local markets just to fulfill the requirement and 
maintain the low cost production which in turn can be very 
harmful for the patients consuming these drugs 
unknowingly. In many developing and under developed 
countries, there are no proper govern on quality of the drugs 
supplied in the market under non- certified trade names 
which are readily available at the pharmacists shop and other 
medical stores. 
 During the literature survey it was also found that along 
with its benefits in treatment of depression, paroxetine do 
possess some serious health risks. Patients with depression 
are at a high risk of suicide attempts [5]. The European 
Medicines Agency's (EMEA) Committee for Medicinal 
Products for Human Use (CHMP) also issued a warning 
regarding prescription of paroxetine to children and also 
asked to closely monitor adult patients showing suicidal 
tendency and/or suicidal thoughts. Paroxetine is also related 
with withdrawal symptoms and that is why it is 
recommended to gradually reduce the dose over several 
weeks or months if decision of withdrawal is made [6]. A 
survey carried out by Food and Drug Administration in 2004 
on children prescribed with paroxetine showed 2.7-fold raise 
in suicide behavior and ideation as compared to placebo. The 
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trend for increased suicidality was observed in both trials for 
depression and for anxiety disorders [7]. 
 Paroxetine and its metabolites in human plasma, human 
serum, and in pharmaceutical preparations have been 
quantified either by high-performance liquid 
chromatography (HPLC) or by gas chromatography. Several 
methods have been developed for the determination of 
paroxetine in plasma, including HPLC with ultraviolet [5, 6], 
fluorescence (without or with derivatization using 
dansylchloride) [7-9], mass spectroscopy (MS) [10, 11], 
diode array detection [12,13], or gas chromatography with 
MS detection [14,15] and applied therapeutic drug level 
monitoring. Only few methods have been published for the 
simultaneous determination of paroxetine and its metabolites 
in plasma, using HPLC with UV [2,16]; or applied to 
pharmacokinetic, therapeutic drug level monitoring, 
toxicological screening or forensic cases [17]. 
 The purpose of this work is to develop a rapid, simple, 
cost effective and selective HPLC procedure for the 
screening of paroxetine in pharmaceutical preparations, 
which is one of the most popular antidepressant widely 
prescribed for the treatment of depression and related mood 
disorders, using C18 column and electrochemical detection. 
The suggested method must be validated following FDA 
indications in terms of selectivity, sensitivity, linearity, 
repeatability, reproducibility, robustness and recovery [18]. 
2. EXPERIMENTAL 
2.1. Materials 
 Standard of paroxetine (purity > 99.99%) was kindly 
gifted from Zydus Health care, Sikkim, India. Other 
pharmaceutical samples (Depox, Pari-CR, Parotin, Pexep, 
Raxit, etc) were procured from the pharmacists of local 
market at Sagar, India. Some of them were gifted by medical 
practitioners. Paroxetine-STADA was procured from 
pharmacist in Castellon, Spain. HPLC grade acetonitrile and 
methanol were purchased from Scharlau, Barcelona. Sodium 
dihydrogenphosphate monohydrate, potassium chloride, and 
HCl were from Panreac, Barcelona. NaOH was from 
Scharlab, Barcelona (all were > 99% purity). Ultrapure water 
used was prepared by using Millipore throughout the study. 
2.2. Instrumentation 
 An Agilent Technologies chromatograph (Model 
HP1100, Palo Alto, CA, USA), equipped with a quaternary 
pump, an autosampler, a UV-Vis and electrochemical 
(Model HP 1049A) detectors was used. Monitoring was 
carried out at 230 nm with UV detector, and 0.9 V with 
electrochemical detector using Ag/AgCl electrode as a 
reference electrode and glassy carbon as the working 
electrode. A Shimadzu double beam UV-Vis. Spectrophoto-
meter UV-210 system shimadzu corporation (Kyoto, Japan) 
was used to measure the spectra. Another chromatographic 
system i.e. Shimadzu Prominence HPLC, Shimadzu 
Corporation, equipped with an isocratic pump LC-20 AT 
prominence pump, an autosampler SIL-20AC and a diode 
array detector SPD-M20A (190-800 nm) was used. The 
flowrate was 1.0ml/min and the injection volume of 
autosampler was set at 20l. A Kromasil C18 column (5m 
particle size, 120mm  4.6mm i.d.) Scharlab, was employed 
for the analytical separation. The chromatographic data was 
acquired by means of personal computer connected to the 
chromatograph by means of Shimadzu LC workstation “LC 
solution software”, version1.22SP1 and “HP Chemstation” 
for Agilent HPLC. 
 The pH of the mobile phase was measured with a Crison 
pH meter (Model micro pH 2001, Barcelona), equipped with 
a combined Ag/AgCl/glass electrode Crison GLP 22, 
Barcelona. 
2.3. Standard and Pharmaceutical Sample Preparation 
 The commercially available tablets of paroxetine were 
weighed and powdered using pastel mortars. A portion of the 
powder equivalent to about 10 mg/ml was weighed 
accurately, transferred to a 100 mL calibrated flask and 
suspended in methanol for analysis. The samples were 
filtered through a 0.45m nylon membrane filter, and then 
further diluted before injection. 
2.4. Mobile Phase Preparation 
 For mobile phase preparation, various combinations of 
methanol:water and acetonitrile:water were prepared 
buffered to pH 7, pH 5 or pH 3 using 0.01 NaH2PO4 buffer 
salt, 0.001M KCl and adjusting the pH using NaOH or HCl. 
The results obtained showed better response in 
acetonitrile:water combinations, buffered to pH 3. All 
solvents were filtered through 0.45m filter paper and 
degassed. 
3. RESULT AND DISCUSSION 
3.1. Development and Optimization of the HPLC Method 
 The dissociation constant (pKa) for paroxetine is 9.9 
(Table 1) which suggests that it is a non-protonated 
compound and falls beyond the working pH range of column 
(3 - 7), still to check the effect of pH paroxetine was injected 
using the three selected pH i.e. (3; 5 and 7), no change was 
observed in retention time but on the basis of other chro-
matographic parameters i.e. efficiency (N) and asymmetry 
(B/A), pH 3 was selected for the further study. The partition 
coefficient (log P (o/w)) of paroxetine is 3.95; suggesting 
that the compound is highly hydrophobic in nature. Based on 
that, various mobile phase combinations such as methanol: 
water and acetonitrile: water at different concentrations was 
used (Table 2). The results obtained using combination of 
acetonitrile: water gave better chromatographic parameters 
i.e. peak shape (more Gaussian), asymmetry (close to 1.000), 
efficiency (higher) and retention time (lower, but > 2.00 
min). So for further analysis combination of acetonitrile: 
water (40:60) buffered to pH 3 was selected (Fig. 1). Under 
these conditions, paroxetine was eluted in less then 10 min, 
lower than the time obtained in previous works [6,7,17]. 
3.2. Study of Oxidation Potential 
 Paroxetine is the only drug amongst SSRIs which is 
electrochemically active. The benefit of such kind of 
compound is that the interference from similar group is 
nullified, which assures the selectivity of the method. Then 
the methodology show higher specificity than previous 
works based on HPLC coupled to UV-Visible [5,6,15,17], 
fluorescence [7,9,12,16] or MS detectors [10,11]. 
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Fig. (1). Standard chromatogram of a standard solution of 10 
ng/mL of paroxetine using the optimum mobile phase comprising 
acetonitrile: water (40:60) at pH 3, with electrochemical detection 
at 0.9 V. 
Table 1. Structure and Physical Properties of Paroxetine 
 
Structure 
Dissociation  
Constant 
Partition  
Coefficient 
 
9.9 3.95 
 
Table 2. Retention Behavior of Paroxetine Using Various 
Combination of Methanol, Acetonitrle and Water 
Used as Mobile Phase 
 
S. No. Mobile Phase Ratio Retention Time (min) 
1. MeOH: H2O 75:25 10.42 
2. MeOH: H2O 25:75 13.84 
3. MeOH: H2O 100:0 7.6 
4. MeOH: H2O 50:50 7.1 
5. MeOH: H2O 80:20 - 
6. Acetonitrile:H2O 30:70 14.9 
7. Acetonitrile:H2O 40:60 6.6 
8. Acetonitrile:H2O 45:55 5.2 
9. Acetonitrile:H2O 50:50 3.2 
10. Acetonitrile:H2O 60:40 2.8 
 
 In order to select the optimum oxidation potential for 
paroxetine, hydrodynamic voltammogram was plotted (Fig. 
2). The potential applied varies between +0.1 to +0.9 V, in 
0.1 V steps up to 0.6 V and then after at an interval of 0.05 
V. By observing the results obtained for paroxetine it was 
concluded that paroxetine starts oxidizing above 0.5 V and 
reaches the maximum at 0.9 V following which a reduction 
is observed. Therefore on the basis of results obtained 0.9 V 
was selected as the potential for further study. 
Fig. (2). Oxidation curve for paroxetine 
3.3. Linearity and Limit of Detection 
 Calibration curves were constructed for paroxetine using 
the areas of the chromatographic peaks observed at eight 
increasing concentrations, each calibration level was 
analyzed 6 times. The concentrations were in the range 0.5-
50 ng/ml using electrochemical detection, while 50-500 
ng/ml for UV. The calibration parameters (slopes and 
intercepts) using electrochemical detection were higher than 
those obtained with UV detection, and then electrochemical 
detection was selected for the analysis of paroxetine. The 
regression curve was: 
A = (572 ± 2) [paroxetine (ng/mL)] + (2.3 ± 0.1) r2 > 0.9999 
 The limit of detection (LOD) and quantification (LOQ) 
for the drug were determined with the 3s and 10s criterion 
respectively, using a series of 10 solutions (10 to 0.01 ng/ml) 
containing low concentrations of the drug to calculate s. The 
results were based not only on the standard deviation of the 
response, but also on the slope of the calibration curve. LOD 
(0.005 ng/mL) and LOQ (0.01 ng/mL) indicate that the 
procedure is sensitive enough for the routine pharmaceutical 
and biological analysis. Sensitivity and linearity were higher 
than obtained in previously published works [5, 
6,7,9,10,12,15-17]. 
3.4. Repeatability and Intermediate Precision 
 Repeatability was evaluated by analyzing five replicates 
of three standard solutions in increasing concentrations (1; 
2.5 and 5 ng/mL), and reproducibility was evaluated using 
the same standard solutions five different days over a period 
of two months. The precision was determined as the CV (%) 
of the results. Intraday precision was: 0.259; 0.144 and 
0.119% (respectively), whereas interday precision was: 
0.0 0.2 0.4 0.6 0.8 1.0
volts
ox
id
at
io
n
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0.538; 0.225 and 0.135% (respectively). The low variability 
and high precision of the results obtained in different days 
are evident, which indicate the usefulness of the method. The 
method was more precise than in other previously published 
papers [5,6,7,9,10,11,12,15-17]. 
 (a) 
 
(b) 
 
Fig. (3). Chromatograms corresponding to paroxetine in 
pharmaceutical preparations: (a) Pharmaceutical containing 
paroxetine (Raxit) procured from Spain. (b) Pharmaceutical 
containing paroxetine (Parotin) procured from India. 
3.5. Robustness 
 The developed method was found to be robust based on 
the fact that the small deliberate changes in the conditions 
did not have any significant effect on the chromatographic 
behavior of the analyte. The chromatographic conditions 
such as concentration of mobile phase and value of pH were 
slightly altered. The effects of slight changes in applied 
detection potential and flow-rate were also studied. Variation 
of the flow rate had stronger influence on the retention of the 
studied compounds than other selected parameters. However, 
the variations in all the parameters (R.S.D.) had no 
significant effect on retention time (< 3.5%), efficiency (< 
0.4%) and asymmetry (< 6.8%). The results obtained are 
summarized in Table 3. 
3.6. Analysis of Paroxetine in Pharmaceutical Preparations 
 The contents of some pharmaceutical formulations 
commercially available in India and Spain were determined 
using the developed method. Paroxetine in India and Spain 
sold under various trade names gave the result similar to that 
mentioned on the wrapper. All the available drugs were 
diluted to inject in the chromatographic system an amount of 
analyte into the linear range. In the obtained chromatograms, 
the paroxetine was eluted without interferences from other 
substances of the matrix, then proving the selectivity of the 
suggested methodology. The results showed satisfactory 
recoveries (99.7 - 100.7%), as shown in Table 4. Accuracy 
obtained using this method were higher than previously 
published works [5-7, 9-12, 15-17]. Fig. (3) shows two 
chromatograms corresponding to paroxetine in pharma-
ceutical preparations. 
4. CONCLUSIONS 
 The results obtained from the above study indicates that 
the HPLC procedure developed herein could easily be used 
for the determination of paroxetine in pharmaceutical 
preparations with an analysis time below 10 min., using 40% 
acetonitrile and 60% water, buffered at pH 3. The procedure 
is sensitive enough to monitor paroxetine in clinical samples 
and pharmaceuticals. The high values of LOD and LOQ 
make the method more applicable for quality control labs. 
The method was successfully applied for the analysis of 
paroxetine in pharmaceutical preparations with good 
accuracy and precision. The developed method is fast, 
robust, easy to handle as well as per sample analysis cost is 
also low. The next step of the research would be to apply this 
methodology to the analysis of clinical and biological 
Table 3. Robustness Study 
 
Chromatographic Parameter Variation Retention Time (min) N B/A Peak Area 
Acetonitrile amount (%) of 
mobile phase 
38-42 7.23 ± 0.15 
(2.1%) 
2653 ± 5 
(0.2%) 
1.89 ± 0.13 
(6.8%) 
 2939 ± 10 
(0.3%) 
pH 2.8 - 3.2 7.20 ± 0.10 
(1.4%) 
2650 ± 10 
(0.4%) 
1.91 ± 0.07 
(3.7%) 
 2931 ± 4 
(0.1%) 
Flow rate 
(mL/min) 
0.9 - 1.1 7.2 ± 0.3 
(3.5%) 
2653 ± 4 
(0.2%) 
1.94 ± 0.05 
(2.3%) 
2928 ± 5 
(0.2%) 
Applied voltage (V) 0.88 - 0.92 V 7.17 ± 0.06 
(0.8%) 
2653 ± 5 
(0.2%) 
1.94 ± 0.04 
(2.1%) 
2870 ± 210 
(7.3%) 
(n = 6). 
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samples, as serum, plasma and urine; and the analysis of 
paroxetine derivatives. 
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Table 4. Absolute Recovery of Paroxetine in Various Pharmaceutical Preparations 
 
S. No. Commercially Procured Pharmaceutical Preparation Found (g/ml) Mean±S.D. Absolute Recoveries (% Mean) 
1. Depox 9.6±1.9 100.5% 
2. Pari-CR 9.5±1.3 99.7% 
3. Parotin 9.5±1.6 99.8% 
4. Pexep 9.6±1.7 100.4% 
5. Raxit 9.6±1.6 100.7% 
